Imatinib Mesylate (Gleevec(TM))-induced Lichenoid Drug Eruption Improved by Tentative Dose-reduction and Topical Steroid.
- Author:
Jung Hoon YANG
1
;
Jung Woong SHIN
;
Hyung Dong KIM
;
Young Lip PARK
;
Sung Yul LEE
;
Kyu Uang WHANG
Author Information
1. Department of Dermatology, Soonchunhyang University College of Medicine, Seoul, Korea. snolomas@schmc.ac.kr
- Publication Type:Case Report
- Keywords:
Gleevec(TM);
Imatinib mesylate;
Lichenoid drug eruption
- MeSH:
Benzamides;
Drug Eruptions;
Gastrointestinal Stromal Tumors;
Humans;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive;
Mesylates;
Phosphotransferases;
Piperazines;
Pyrimidines;
Receptors, Platelet-Derived Growth Factor;
Tyrosine;
Imatinib Mesylate
- From:Korean Journal of Dermatology
2011;49(2):155-158
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Imatinib mesylate (Gleevec(TM)) is an oral anticancer drug. It works as a selective and competitive inhibitor of tyrosine kinases such as bcr-abl protein, c-kit, and platelet-derived growth factor receptors (PDGFR). Gleevec(TM) is a first-line therapeutic agent for chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors, but causes various adverse cutaneous reactions. We herein report on a case of lichenoid drug eruption induced by Gleevec(TM) in a patient with a malignant gastrointestinal stromal tumor.
